Temporal lobe epilepsy. Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
Conditions
Interventions
Intervention 1: Intervention group: In this group 10 mg Donepezil is prescribed daily for 16 weeks that is produced by Jalinous Pharmacological Company. Intervention 2: Intervention group: In this gro
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Having age between 18-55 years Having temporal lobe epilepsy Have no other neurological disease Use no medications for treating cognitive disorders willingness to participate in this study
Exclusion criteria
Exclusion criteria: Having mental retardation Having progressive neurological disease Having sensitivity to Memantine or Donepezil
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The score of Montreal Cognitive Assessment test. Timepoint: Before and immediately after intervention. Method of measurement: Montreal Cognitive Assessment questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of sensitivity to Memantine. Timepoint: During intervention. Method of measurement: observation.;Incidence of sensitivity to Donepezil. Timepoint: During intervention. Method of measurement: observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarjan Oustad
Esfahan University of Medical Sciences
Outcome results
None listed